{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000867","form_type":"8-K","ticker":"NUS","cik":"0001021561","company_name":"NU SKIN ENTERPRISES, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.718345+00:00","generated_at":"2026-05-28T02:37:18.380384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Nu Skin Q4 prelim revenue at high end of guidance; closed Mavely deal for $250M","bullets":["Q4 2024 preliminary revenue at high end of company's guidance range.","Recently closed strategic transaction of Mavely for $250 million.","Full Q4 and FY2024 results to be announced on Feb. 13, 2025.","CEO Ryan Napierski and CFO James Thomas to present at ICR Conference on Jan. 14."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000867","json":"https://secwatch.observer/filing/0001140361-25-000867.json","markdown":"https://secwatch.observer/filing/0001140361-25-000867.md","text":"https://secwatch.observer/filing/0001140361-25-000867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1021561/000114036125000867/0001140361-25-000867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1021561/000114036125000867/ef20041411_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:37:18.380384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}